Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments

US10787501B1 · kind B1 · utility

Assignee

• REGENERON PHARMACEUTICALS, INC. · US

Inventors

• Robert Babb · River Edge, US
• Alina BAUM · Pleasantville, US
• Gang Chen · Sammamish, US
• Cindy Gerson · Ardsley-on-Hudson, US
• Johanna Hansen · Greenwich, US
• Tammy T. Huang · Goldens Bridge, US
• Christos Kyratsous · Dobbs Ferry, US
• Wen-Yi Lee · New Hyde Park, US
• Marine Malbec · Port Chester, US
• Andrew J. Murphy · Croton-on-Hudson, US
• William Olson · Ossining, US
• Neil Stahl · Carmel, US
• George D. Yancopoulos · Elmhurst, US

Key dates

• Filing date: Jun 25, 2020
• Grant date: Sep 29, 2020
• Expiry date: Jun 25, 2040

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infections).